Clinical Trial: Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder

U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07330648) titled 'Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder' on Nov. 24, 2025.

Brief Summary: A placebo-controlled superiority design was used to evaluate the efficacy of 40 mg/ day of Crisugabalin capsules in the treatment of GAD.

Study Start Date: Oct. 10, 2025

Study Type: INTERVENTIONAL

Condition: Generalized Anxiety Disorder

Intervention: DRUG: Crisugabalin 20mg bid

Crisugabalin 20mg bid Crisugabalin 20mg, orally twice a day; treatment period: 8 weeks fixed dose. Open-label extension phase: Crisugabalin 40mg, orally twice a day; treatment period: 4 weeks fixed dose.

DRUG: Venlafax...